US 10451610
Prediction of response to PARP inhibitors and combinational therapy targeting C-MET and PARP1
granted A61KA61K31/4184A61K31/4425
Quick answer
US patent 10451610 (Prediction of response to PARP inhibitors and combinational therapy targeting C-MET and PARP1) held by The Board of Regents of the University of Texas System expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K31/4184, A61K31/4425, A61K31/444, A61K31/5377